Economic Evaluation of Fidaxomicin for the Treatment of Clostridium Difficile Infections (CDI) also Known as Clostridium Difficile-Associated Diarrhoea (CDAD) in Spain

Reinoso, Javier Cobo; Cerrato, Santiago Grau; Pueyo, Josep Mensa; Lletí, Miguel Salavert; Toledo, A.; Anguita, Paula; Rubio-Terrés, Carlos; Rubio-Rodríguez, Darío

doi:10.1016/j.jval.2014.08.2501

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of the 13 EEs reported as full publications, six [ 26 , 27 , 46 , 58 , 62 , 65 ] had previously been presented at a conference [ 38 , 41 , 45 , 52 , 63 , 66 ] and posters were sourced for all except one [ 45 ]. For the remaining EEs, the data were reported in abstract ( n = 7) [ 36 , 39 , 49 , 53 , 54 , 56 , 57 , 59 ] or poster form ( n = 7) only [ 40 , 43 , 44 , 47 , 51 , 60 , 61 , 64 ].…”

Section: Resultsmentioning

confidence: 99%

A Systematic Literature Review of Economic Evaluations of Antibiotic Treatments for Clostridium difficile Infection

Burton¹,

Mitchell²,

Watt

2017

PharmacoEconomics

View full text Add to dashboard Cite

Background and Objective Clostridium difficile infection (CDI) is associated with high management costs, particularly in recurrent cases. Fidaxomicin treatment results in lower recurrence rates than vancomycin and metronidazole, but has higher acquisition costs in Europe and the USA. This systematic literature review summarises economic evaluations (EEs) of fidaxomicin, vancomycin and metronidazole for treatment of CDI.MethodsElectronic databases (MEDLINE®, Embase, Cochrane Library) and conference proceedings (ISPOR, ECCMID, ICAAC and IDWeek) were searched for publications reporting EEs of fidaxomicin, vancomycin and/or metronidazole in the treatment of CDI. Reference bibliographies of identified manuscripts were also reviewed. Cost-effectiveness was evaluated according to the overall population of patients with CDI, as well as in subgroups with severe CDI or recurrent CDI, or those at higher risk of recurrence or mortality.ResultsOverall, 27 relevant EEs, conducted from the perspective of 12 different countries, were identified. Fidaxomicin was cost-effective versus vancomycin and/or metronidazole in 14 of 24 EEs (58.3%), vancomycin was cost-effective versus fidaxomicin and/or metronidazole in five of 27 EEs (18.5%) and metronidazole was cost-effective versus fidaxomicin and/or vancomycin in two of 13 EEs (15.4%). Fidaxomicin was cost-effective versus vancomycin in most of the EEs evaluating specific patient subgroups. Key cost-effectiveness drivers were cure rate, recurrence rate, time horizon, drug costs and length and cost of hospitalisation.ConclusionsIn most EEs, fidaxomicin was demonstrated to be cost-effective versus metronidazole and vancomycin in patients with CDI. These results have relevance to clinical practice, given the high budgetary impact of managing CDI and increasing restrictions on healthcare budgets.OtherThis analysis was initiated and funded by Astellas Pharma Inc.Electronic supplementary materialThe online version of this article (doi:10.1007/s40273-017-0540-2) contains supplementary material, which is available to authorized users.

show abstract

Section: Resultsmentioning

confidence: 99%

A Systematic Literature Review of Economic Evaluations of Antibiotic Treatments for Clostridium difficile Infection

Burton¹,

Mitchell²,

Watt

2017

PharmacoEconomics

View full text Add to dashboard Cite

show abstract

“…In recent years, studies had compared the recurrence rate and average hospital stay of CDI patients treated with 2 antibiotics, which showed that the cost-effectiveness of fidaxomicin in the treatment of CDI was more advantageous than that of vancomycin. [25][26][27] However, drug prices and hospitalization costs vary greatly in different regions, and the cost-effectiveness of drugs should be determined according to local conditions.…”

Section: The Cost-effectiveness Of Fidaxomicin Versus Vancomycin In T...mentioning

confidence: 99%

Efficacy of fidaxomicin versus vancomycin in the treatment of Clostridium difficile infection: A systematic meta-analysis

Zhao,

Wu,

Geng

et al. 2024

Medicine

View full text Add to dashboard Cite

Purpose: To compare the efficacy, recurrence rate, adverse event rate and mortality of fidaxomicin compared with vancomycin in treating different types of Clostridium difficile infection (CDI). Methods: A systematic search was conducted on PubMed, Embase, Web of Science, Cochrane Library and clinical trial registration databases for research on fidaxomicin versus vancomycin in the treatment of CDI and the retrieval period extended from the establishment of the database to July 22, 2022. A total of 15 studies were included, including 8 RCTs and 7 retrospective cohort studies. Results: Results showed that there was no significant difference in the overall efficacy of the treatment between fidaxomicin and vancomycin, and results in the subgroups of CDI hypervirulent strains and recurrent CDI were obtained, but vancomycin was more effective than fidaxomicin in the treatment of severe CDI (RR = 0.94, 95% CI: 0.90–0.98, P < .01). Results showed that fidaxomicin is superior to vancomycin in terms of 40-day recurrence rate (RR = 0.52, 95% CI: 0.38–0.70, P < .01), 60-day recurrence rate (RR = 0.38, 95% CI: 0.21–0.69, P < .01) and 90-day recurrence rate (RR = 0.62, 95% CI: 0.50–0.77, P < .01). For the recurrence rate of the treatment in CDI hypervirulent strains, severe CDI and recurrent CDI, there was no significant difference between the 2 groups. In addition, there was no significant difference in the incidence of clinical adverse reactions, and same outcomes appeared in all-cause mortality at 40-day, severe CDI and recurrent CDI, but fidaxomicin was superior to vancomycin in all-cause mortality over 60-day (RR = 0.57, 95% CI: 0.34–0.96, P = .03). Conclusion: There were no significant differences between fidaxomicin and vancomycin in the treatment of CDI in therapeutic effectiveness and adverse reactions, while fidaxomicin was superior to vancomycin in terms of recurrence rate and long-term mortality, and vancomycin is more effective in treating severe CDI.

show abstract

Economic Evaluation of Fidaxomicin for the Treatment of Clostridium Difficile Infections (CDI) also Known as Clostridium Difficile-Associated Diarrhoea (CDAD) in Spain

Cited by 2 publications

References 0 publications

A Systematic Literature Review of Economic Evaluations of Antibiotic Treatments for Clostridium difficile Infection

A Systematic Literature Review of Economic Evaluations of Antibiotic Treatments for Clostridium difficile Infection

Efficacy of fidaxomicin versus vancomycin in the treatment of Clostridium difficile infection: A systematic meta-analysis

Contact Info

Product

Resources

About